Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Panagiotis Konstantinopoulos, MD, PhD
With
This is a non-randomized, open-label, two-stage, phase 2 trial of avelumab in combination with ATR inhibitor (ATRi) M1774 in participants with ARID1A-mutated endometrial cancers who have received prior immunotherapy. The U.S. Food and Drug Administration (FDA) has not approved avelumab for ARID1A-mutated recurrent endometrial cancer but it has been approved for other uses. The FDA has not approved M1774 as a treatment for any disease. The research study procedures including screening for eligibility, in-clinic treatment visits, blood tests, urine tests, Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans, and electrocardiograms (ECGs). Participants will receive study treatment for up to 2 years and will be followed for up to 3 years until the study is complete. It is expected that about 25 people will take part in this research study. EMD Serono is supporting this research study by providing the study drugs avelumab and M1774.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted